CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Allison Transmission Q3 sales jump 121%, beat estimates

By Reuters News


Overview

  • US transmission maker's Q3 sales rose 121% yr/yr, beating analyst expectations

  • Adjusted diluted EPS for Q3 rose 59% yr/yr

  • Company repurchased $57 mln in stock during Q3


Outlook

  • Company now expects 2026 net income of $645-$685 mln


Result Drivers

  • TRUCK DEMAND - Higher volumes for medium-duty and Class 8 vocational trucks in North America On-Highway market drove record revenue

  • OFF-HIGHWAY ACQUISITION - Addition of Off-Highway business unit, with strong Mining and Construction & Material Handling demand, boosted consolidated sales

  • PRICE INCREASES - Price increases on certain products contributed to revenue growth, partially offset by higher material and manufacturing costs


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$1.53 bln

$1.47 bln (7 Analysts)

Q3 EPS

$2.30

Q3 Net Income

$191 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the heavy machinery & vehicles peer group is "buy"

  • Wall Street's median 12-month price target for Allison Transmission Holdings, Inc. is $135.00, about 24.9% above its October 30 closing price of $108.05

  • The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago


Reuters Recommended Reads

  • Nov 2 - Marriott lifts annual room revenue growth forecast on resilient travel demand

  • Nov 2 - Marriott tops Q3 revenue, profit estimates

  • Nov 2 - IDEXX raises forecast, betting diagnostics can offset weak vet visits


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.